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ABSTRACT
A review is presented on different analytical techniques used for quantitative analysis of selected anticoagulants dabigatran, rivaroxaban, and 
prasugrel. Efforts have been made to collate all the relevant references to the extent possible. The review discusses the advantages and disadvantages 
of the cited analytical techniques, which will help to give insights into the methods used for estimation of selected anticoagulants such as dabigatran, 
rivaroxaban, and prasugrel, from clinical isolates, and its dosage forms. The review highlights the basic as well as advanced techniques performed for 
estimating dabigatran, rivaroxaban, and prasugrel. The techniques illustrated here have been demonstrated to be useful for quantitative determination 
of selected anticoagulants and may find application in analyzing other related properties.
Keywords: Rivaroxaban, Dabigatran, Quantification, Prasugrel, Analyte.
INTRODUCTION
A blood clot is a clump of blood that has changed from a liquid to a gel-
like or semisolid state. Clotting or coagulation is a necessary process that 
can prevent you from losing too much blood in certain instances, such as 
when you’re injured or cut. When a clot forms inside one of your veins, it 
won’t always dissolve on its own. This can be a very dangerous and even 
life-threatening situation. There are many types of blood coagulation – 
deep vein thrombosis, pulmonary embolism, coronary embolism, and 
cerebral embolism. Hence, blood thinners are used (Anticoagulant), it 
is necessary to treat and prevent various blood clot in vivo condition.
In current scenario, numerous intravenous and oral anticoagulants 
are used for treatment of in vivo blood coagulation. Those are Indirect 
thrombin inhibitors-Heparin derivatives Fondaparinux, danaparoid, 
enoxaparin and dalteparin, Direct thrombin inhibitors- Lepirudin, 
Bivaluridin, Hirudin or Leechin and Oral ones- Coumarin derivatives-
Nicoumalone, Warfarin, Indanedione derivatives- Phenindione and 
Diphendione, Director factor-Xa inhibitors-Apixaban, Rivaroxaban, 
Edoxaban, Platelet aggregator inhibitor-Clopidogrel, Prasugrel and Oral 
direct thrombin inhibitors-Dabigatran etexilate etc. [1].
Dabigatran is rapid-acting competitive and reversible direct inhibitor of 
thrombin. It is chemically as N-[2-[4-[N-(Hexyloxycarbonyl) amidino] 
phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcarbonyl]-N-
(2-pyridyl)-beta-alanine ethyl ester (Fig. 1). It is a light yellow to dark 
yellow solid with the empirical formula C34H41N7O5 and molar mass of 
627.746 g/mol.
Rivaroxaban chemically described as 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-
oxomorpholin-4-yl) phenyl]-1, 3-oxazolidin-5-yl] methyl] thiophene-
2-carboxamide (Fig. 2), it is a highly selective direct Factor Xa inhibitor. It is 
an empirical formula C19H18ClN3O5S and molecular weight of 435.882 g/mol.
Prasugrel chemically prasugrel chemically is 5-[2-cyclopropyl -1-
(2- fluorophenyl)-2-oxoethyl]-4, 5, 6, 7-tetra hydro thieno [3, 2- c] 
pyridin-2-yl acetate (Fig. 3), it reduces the aggregation (“clumping”) 
of platelets by irreversibly binding to P2Y12 receptors. It is empirical 
formula C20H20FNO3S and molecular weight of 435.882 g/mol.
In this article, we reviewed some analytical methods for the estimation 
of dabigatran, rivaroxaban, and prasugrel in pure drug and dosage forms.
QUANTITATIVE ANALYTICAL TECHNIQUES FOR SELECTED 
ANTICOAGULANTS
Analytical techniques for quantitative analysis help an analyst to 
accurately determine the concentration of an individual component 
in the test sample. The separation of the analyte is often performed 
before analysis by classical methods or during analysis by instrumental 
methods. Wet analytical methods such as titrations, precipitations, and 
extractions are used to estimate a drug or an analyte.
Instrumental methods for quantification of analyte use chromatography, 
electrophoresis, etc., for separation and physical properties such as 
absorption, fluorescence, conductivity, and light scattering are utilized 
to measure the analyte accurately and precisely.
The selected anticoagulants – dabigatran, rivaroxaban, and prasugrel 
can be estimated quantitatively using different methodologies. There 
are innumerable publications based on this simple basic technique, but 
a few were selected here.
Quantitative determination of dabigatran, rivaroxaban, and 
prasugrel
Spectroscopy
It is impossible to envision any literature reference not taking advantage 
of this powerful technique in assaying dabigatran. Many studies have 
focused on this technique and have performed quantitative estimation 
of dabigatran as an active pharmaceutical ingredient or in its dosage 
form, either when formulated alone or with other active components.
Spectrophotometric method used for the analysis of tablets of 
dabigatran was cited by Jayavarapu et al. [2]. The method used 0.1 N 
hydrochloric acid as the solvent due to stability in HCl. The samples 
were scanned and analyzed at 326 nm wavelength. The method was 
found to be accurate, precise, and linear over the concentration ranges 
of 3–2 μg/mL. Similarly, Prajapati et al. [3] published spectrophotometric 
method for estimation of dabigatran etexilate in bulk and its 
pharmaceutical dosage form. Dabigatran etexilate was estimated at 
313 nm. The linearity concentration ranges from 3 to 15 µg/mL. The 
method was carried out zero-order spectrophotometric method 
applied successfully for the analysis of the drug in the pure and 
pharmaceutical dosage form. Hepsebah et al. [4] developed 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i4.29954
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spectrometric dissolution method for dabigatran etexilate mesylate 
capsules, using 0.01 N HCl as dissolution media, apparatus as USP 
Type 1 Basket, rpm as 100, dissolution media temperature as 37±0.5ºC, 
dissolution volume as 500 ml, dissolution time point as 30 mts, and 
detection wavelength at 325 nm. The developed method resulted in 
dabigatran etexilate exhibiting linearity in the range 1.25–10 μg/ml. 
Harini et al. [5] developed and validated a simple, accurate, precise, and 
cost-effective UV-Spectrophotometric method for the estimation of 
dabigatran etexilate mesylate, the method was performed at 226 nm 
and the samples were prepared with methanol as solvent. Linearity 
range was found at 2–10 μg/ml in UV with a correlation coefficient (R) 
0.999. The proposed method was simple, precise, and accurate and can 
be used for the analysis of drug in bulk form. El-Din et al. [6] developed 
three rapid, accurate, and very simple derivative spectrophotometric 
methods for rivaroxaban and clopidogrel assay in their binary mixture 
and tablet dosage forms. First derivative spectrophotometric method, 
derivative amplitudes were measured at the zero crossing wavelength 
of 289 and 249.5 nm for estimation of rivaroxaban and clopidogrel, 
respectively. The linearity is over the range of 2.0–20.0 μg/ml for 
rivaroxaban and 5.0–60.0 μg/ml for clopidogrel. Seshamamba and 
Sekaran [7] described two simple spectrophotometric methods 
(I and II) for the determination of rivaroxaban in bulk and tablets. The 
method I is based on the reaction of rivaroxaban with 4-Chloro-7-
nitrobenzo-2-oxa-1, 3-diazole in alkaline medium. Method II involved 
the reaction of rivaroxaban with p-Dimethylamino cinnamaldehyde in 
acidic medium. The reactions products were measured at 405 nm and 
545 nm for methods I and II, respectively. Sekaran et al. [8] developed 
UV-spectrophotometric method for the quantification of rivaroxaban in 
bulk. Rivaroxaban was estimated at 270 nm in dimethyl sulfoxide. The 
linearity range was found to be 2–20 μg mL–1. Sreeja et al. [9] developed 
two simple, sensitive, and economic spectrophotometric methods for 
the determination of desvenlafaxine in pure and its pharmaceutical 
formulations. In which proposed methods are based on the reaction of 
oxidative coupling of desvenlafaxine with 3-methyl-2-
benzthiazolinonehydrazone (Method A) and 2, 2’ bipyridyl (Method B) 
in the presence of ferric chloride. The colored complex produced was 
measured at 663 nm, 522 nm for method A and B, respectively, against 
the reagent blank. The optimum experimental parameters for the color 
productions are selected. Bagga et al. [10] developed that simple and 
cost-effective colorimetric method is described for the determination of 
prasugrel in pure form and pharmaceutical formulations. The 
determination of the drug in pharmaceutical formulations is based on 
the drugs redox reaction with Folin–Ciocalteu reagent (Phenol reagent). 
The linearity range for prasugrel of blue chromogen produced at a 
wavelength of detection 725 nm was obtained as 10–50 µg/ml. The 
absorbance was found to increase linearly with increasing concentration 
of prasugrel, which is corroborated by the calculated correlation 
coefficient value of 0.999. Another simple, economical, precise, and 
reliable spectrophotometric method was done by Harshini et al. [11] for 
the estimation of prasugrel. In this method, the formation of chloroform 
extractable complex of prasugrel with bromocresol green this shows 
absorbance maximum at 418 nm. Sowndarya et al. [12] developed a 
simple and cheap UV-spectrophotometric method for the quantitative 
estimation of dabigatrn etexilate (150 mg) in capsules and the 
optimized method uses 0.05 N HCl as a solvent for the estimation of an 
assay of dabigatrn etexilate in capsules at a wavelength of 325 nm. The 
developed method resulted in dabigatrn etexilate exhibiting linearity in 
the range 5–15 μg/ml. The assay precision is exemplified by the relative 
standard deviation of 1.4%. Seshamamba and Sekaran [13] studied and 
revealed the report on the development of two spectrophotometric 
methods (A and B), for the determination of rivaroxaban in bulk and 
Xarelto tablets. Method A involves the formation of colored tris 
(1, 10-phenanthroline)-iron (II) complex, on reaction of rivaroxaban 
with iron (III)-1, and 10-phenanthroline mixture in acidic media. The 
colored complex is spectrophotometrically measured at 525 nm. 
Method B involves the interaction of rivaroxaban with acetaldehyde 
with chloranil, to give colored vinyl amino substituted quinones. The 
colored product exhibit absorption maxima at 655 nm. Beer’s law 
correlating the absorbance with rivaroxaban concentration was obeyed 
Fig. 1: Molecular structure of dabigatran
Fig. 2: Molecular structure of rivaroxaban
Fig. 3: Molecular structure of prasugre
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in the range of 5–62.5 μg/ml and 10–100 μg/ml, for methods A and B, 
respectively. Alvi et al. [14] developed two simple, accurate, and precise 
UV derivative spectrophotometric methods for the simultaneous 
determination of prasugrel and aspirin in synthetic mixture form. The 
first method involves the measurement of second-order derivative 
spectra of prasugrel and aspirin. The zero crossing wavelengths 
267.62 nm and 252.40 nm were selected for estimation of prasugrel 
and aspirin, respectively. In the second method, the first-order 
derivatives of ratio spectra were calculated and used for the 
determination of prasugrel and aspirin by measuring the peak intensity 
at 268 nm and 290 nm, respectively. Çelebier et al. [15] studied that a 
UV-spectrophotometric method was developed for the determination 
of rivaroxaban content in pharmaceutical formulations and the amount 
of rivaroxaban released in tablet dissolution studies. The dissolution 
profile of rivaroxaban was successfully determined with the validated 
method. Sharaf et al. [16] created three rapid, accurate, and very simple 
derivative spectrophotometric methods for rivaroxaban and clopidogrel 
assay in their binary mixture and tablet dosage forms were developed. 
Method (I) is the first derivative spectrophotometric method; derivative 
amplitudes were measured at the zero crossing wavelength of 289 and 
249.5 nm for estimation of rivaroxaban and clopidogrel, respectively. 
Method (II) is a ratio derivative spectrophotometric method. The ratio 
spectra of each drug were derived by dividing its spectra on a constant 
concentration of the other drug as a divisor. Derivative amplitudes were 
measured at 256 nm for rivaroxaban and at 214.5 nm for clopidogrel 
and in Method (III) is absorbance ratio method, the absorbance of both 
drugs was recorded at two wavelengths λ1 (232) iso-absorptive point 
and λ2 (249) λmax of rivaroxaban and clopidogrel. Rajendiran et al. [16] 
developed new analytical methods such as UV Spectroscopy and 
reversed-phase high-performance liquid chromatographic (RP-HPLC) 
for the estimation of prasugrel hydrochloride in bulk and tablet dosage 
form. In the spectroscopic method, prasugrel hydrochloride showed 
maximum absorbance at 252 nm in methanol which is selected as a 
solvent for analysis based on its stability. Beer’s law obeyed in the 
concentration range of 10–60 mcg/ml. In RP-HPLC, the mobile phase 
selected is acetonitrile: trifluroacetic acid in the ratio 45:55% v/v. The 
flow rate was 0.1 ml/min. The linearity range was found to be 
10–60 mcg/ml. The formulation EFIPLT was selected for analysis and 
the amount present was found to be 100.53% and 106.95% for method 
UV and RP-HPLC, respectively. Mehta and Maheshwari [17] developed 
UV-spectrophotometric methods and LC assay methods and validated 
for the determination of rivaroxaban and ticagrelor in the synthetic 
mixture. Spectrophotometric estimation was done by derivative 
spectroscopic method and methanol as solvent. In this method, λ max 
for rivaroxaban and ticagrelor were selected at 295 nm and 249 nm. RP-
HPLC analysis was carried out using Pearless C-18 column (4.6×250 mm, 
5 μ particle size) and mobile phase composed of acetonitrile:10% 
orthophosphoric acid in water pH 4.0 (60:40% v/v) at a flow rate of 
1.0 ml/min and chromatogram was recorded at 249 nm.
Chromatography
Today not a single molecule is analyzed without the use of powerful 
analytical tools such as HPLC, ultra-performance LC (UPLC), and high-
performance thin-layer chromatography (HPTLC).
Geetharam et al. [18] developed simple, precise, accurate, and rapid 
stability indicating that HPLC method was developed and validated for 
the determination of dabigatran etexilate in bulk and capsule dosage 
forms. Chromatographic separation was achieved using mobile phase 
phosphate buffer Ph 4.5 and acetonitrile in the ratio 50:50 with hypersil 
BDS C18 (150×4.6 mm, 5 μm) as stationary phase. Flow rate was 
optimized to 1.2 ml/min and effluents were monitored at 230 nm. The 
retention time was around 3.19. Linearity was observed over a 
concentration range of 9–113 μg/ml with correlation coefficient of 
0.999. Abdallah et al. [19] developed and validated an orthogonal 
stability-indicating testing protocol (RP-HPLC and NP-TLC-
densitometry) for the quantification of Rivaroxaban. It  is an amide 
group-containing oral anticoagulant was subjected to stress conditions 
commonly required for the registration of pharmaceuticals: base and 
acidcatalyzed hydrolysis (0.1 M, 60°C, 3–6 h), oxidation (10% H2O2, 24 
h), photodegradation (300–800 nm, 24 h) and thermal decomposition 
(50°C, 6 h). Two major degradation products were separated and 
identified using TLC and LC/MS/MS, respectively. The Determination 
was carried out over a concentration range of (5.00–50.00 μg/mL) and 
(0.40–12.00 μg/band) with an accuracy of (100.81% ± 1.03) and 
(100.29% ± 1.08) for HPLC and TLC-densitometry, respectively. 
Nagadeep et al. [20] developed and validated RP-HPLC method for 
separation and determination of potential related impurities (starting 
materials and by-products of synthesis, and degradants) of dabigatran 
etexilate drug substance. The separation was accomplished on an 
Inertsil ODS 3V (250 mm×4.6 mm, 5 μm) column connected to a 
photodiode array (PDA) detector using 20 mM ammonium formate 
with 0.1% of triethylamine (TEA) (pH: 5.0 adjusted with formic acid) as 
mobile phase-A and acetonitrile as mobile phase-B, under gradient 
elution. Kumar et al. [21] developed a RP-HPLC bioanalytical method 
development and validation for prasugrel in human plasma using PDA 
detector. The HPLC separation was carried out in an isocratic mode on 
an X-Terra C18 column (4.6×150 mm; 5 μm) with a mobile phase 
consisting of potassium dihydrogen phosphate [pH 3.0] and acetonitrile 
in the ratio of 30:70 v/v at a flow rate of 1.0 mL/min. The run time was 
maintained for 5 min and the detection was monitored at 210 nm. 
Damle and Bagwe [22] developed and validated a simple, selective, and 
rapid stability indicating RP-HPLC method for the estimation of 
dabigatran etexilate analyte and it was resolved on a Neosphere 
C8 (150 mm×4.6 mm) column. The mobile phase consisted of 
methanol: phosphate Buffer (0.01 M pH 3) in the ratio of 60:40 v/v and 
sonicated to degas. It was delivered at a flow rate of 1 ml/min at ambient 
temperature and the retention time was about 4.4±0.05 min. Studies 
were performed on an HPLC system equipped with a PDA detector at 
225 nm. Ishaq et al. [23] designed to develop and validate a simple, 
sensitive, precise, and specific RP-HPLC method for the determination 
of prasugrel in bulk and its tablet dosage forms. Separation was carried 
out by RP chromatography on an inertsil ODS-3V column (5 μm; 
250×4.6 mm2) with a mobile phase composed of 0.02 M potassium 
dihydrogen orthophosphate, 0.02 M dipotassium hydrogen 
orthophosphate in water: acetonitrile (30:70 v/v) in isocratic mode at a 
flow rate of 1 ml/min. The detection was monitored at 210 nm. Sagar 
et al. [24] developed a rapid, simple, precise, accurate, and reproducible 
RP-HPLC method for simultaneous determination of aspirin and 
prasugrel in the tablet dosage form. The estimation was carried out on 
a HIBAR (Lichrospher C18) column with the dimensions of 
250 mm×4.6 mm, 5 μm. Combination of acetonitrile and 0.5% potassium 
dihydrogen phosphate buffer (adjusted to pH-3 using orthophosphoric 
acid) in the ratio of 60:40 was used as mobile phase. The flow rate is set 
at 1.0 ml/min and eluents were monitored at 220 nm. Sahoo and 
Mekap [25] optimized a RP-HPLC procedure to finalize a different 
approach for the estimation of rivaroxaban in tablet dosage form. The 
determination was executed by C18 column (Phenomenex 250×4.6 mm, 
5 μm maintained at 35°C) at 251 nm with a mobile phase (ACN: Water, 
55:45 v/v) and flow of 1.2 ml/min. The retention time found to be about 
3.8 min. Manasa et al. [26] developed a rapid, sensitive, accurate, 
precise, and linear stability indicating RP-HPLC assay method and 
validate as per the ICH guidelines for the estimation of dabigatran 
etexilate mesylate in capsules. The optimized method employs a RP 
column, Phenomenex Kinetex EVO C18 (250×4.6 mm; 5μ), a mobile 
phase of triethylammonium phosphate buffer (pH 2.0):methanol: 
acetonitrile in the proportion of 30:30:40 v/v, flow rate of 0.6 ml/min 
and a detection wavelength of 254 nm using a UV detector. Souri et al. [27] 
studied a stability-indicating HPLC method for the quantitative 
determination of rivaroxaban in pharmaceutical dosage forms. 
Rivaroxaban was subjected to acidic, basic, oxidative, photolytic, and 
thermal conditions for forced stress degradation studies. Considerable 
degradation was observed in all stress degradation tests. Rivaroxaban 
and its degradation products were separated on a Nova-Pak C8 column 
utilizing a mixture of acetonitrile and KH2PO4 50 mM (pH 3.0) 
(40:60, v/v) as the mobile phase, and the chromatogram was recorded 
at 270 nm using a general ultraviolet detector. Seshamamba et al. [28] 
developed simple and sensitive stability indicating HPLC method for 
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the quantification of rivaroxaban in bulk and tablet dosage form. 
Chromatographic separation was achieved on an ACE-Ciano column 
(250 mm×4.6 mm, 5 μm particle size). The mobile phase consists of 0.1 
M sodium acetate and methanol (60:40 v/v) and was delivered at a flow 
rate of 1 mL/min. A UV detector was used for detection. Reddy et al. [29] 
developed and validate RP-HPLC, simple, precise, accurate, and specific 
chromatographic method for the determination of related substances 
of prasugrel in pharmaceutical formulations. HPLC instrument and 
Inert Sustain C18, 75×4.6 mm, 3 μm were used for determination of 
prasugrel and its related substances. The buffer was prepared using 
1.36 g of potassium phosphate monobasic in 1000 mL of water, adjust 
the pH of this solution to 3.30 with a dilute orthophosphoric acid 
solution and mix well. Filter through 0.45 μm nylon filter and degas. The 
buffer used as a mobile phase-A, the mobile phase-B was prepared by 
mixing acetonitrile and water in the ratio of 90:10 (v/v). The flow rate 
of 1.0 mL/min was set with gradient program, the temperature of the 
column compartment maintained at 30°C and ultraviolet detection 
done at 235 nm wavelength. Nawale et al. [30] developed and validate 
new, simple, and selective RP-HPLC method for the quantitative 
determination of dabigatran etexilate and its impurities in the 
pharmaceutical dosage form as per the ICH guidelines. Chromatographic 
analysis was performed on Princeton SPHER-l00 C18 (250×4.6 mm, 5 
μm) HPLC column, maintained at 50°C column temperatures, 6°C 
sample tray temperature, and detection monitored at 225 nm. The 
mobile phase consisted of acetonitrile: phosphate buffer (pH 2.5) 
(33:67 V/V). The flow rate was maintained at 1.0 ml/min. Bhavani et al. 
[31] developing simple, fast, and effective dissolution method for 
dabigatran etexilate mesylate capsules by RP-HPLC and validate as per 
the ICH guidelines. The optimized RP-HPLC method for dissolution 
studies uses a RP column, Phenomenex Luna C18 (250×4.6 mm; 5μ), a 
mobile phase of triethylammonium phosphate buffer 
(pH 3.0):acetonitrile in the proportion of 40:60 v/v, diluent as 0.01N 
HCl, flow rate of 1.0 ml/min, injection volume as 20 μl, and a detection 
wavelength of 341 nm using a UV detector. Balaji et al. [32] developed a 
validated, simple, precise, and stability indicating RP-HPLC method for 
the determination of dabigatran etexilate mesylate in bulk drug and 
dosage form. LC separation was achieved gradient mode on a Zorbax SB 
C18 (4.6×150) mm, 3.5 µm column using mobile phase containing 
solution A (2.72g of potassium dihydrogen phosphate in 1000 ml of 
water) PH 4.5 with orthophosphoric acid solution B (acetonitrile) at 
flow rate 1.0 ml/min. The method employed a linear gradient elution 
and detection wavelength was set at 220 nm. Bernardi et al. [33] 
developed and validated an RP-LC method for the determination of 
dabigatran etexilate in a capsule formulation. The LC method was 
carried out on a Zorbax C18 column (250×4.6 mm id). The mobile phase 
consisted of acetonitrile and a solution of TEA 0.1%, pH 6.0 adjusted 
with phosphoric acid (65 + 35, v/v) at a flow rate of 1.0 mL/min. The 
diode array detector was set at 225 nm. The chromatographic 
separation was obtained with a retention time of 6.31 min. Patel et al. 
[34] a simple and precise stability indicating that HPTLC method has 
been developed and validated for the simultaneous estimation of 
prasugrel and aspirin from dosage form. The method employed TLC 
aluminum plates precoated with silica gel 60 GF 254 as the stationary 
phase. The solvent system comprised carbon tetrachloride: ethyl 
acetate: acetic acid (7.5:2.4:0.1, v/v/v). This system was found to give 
good result for both the drugs (Rf value: of aspirin 0.34 cm and Prasugrel 
0.58 cm). Spectrodensitometric scanning-integration was performed at 
a wavelength of 240 nm. Avachat and Yamgar [35] developed and 
validated a RP-HPLC method for the estimation of rivaroxaban in bulk 
and tablet dosage forms. The separation was achieved on stainless steel 
Purospher® STAR Hibar® C18 analytical column (250 mm×4.6 mm i.d., 
5.0 μm) using acetonitrile and water in the ratio 80:20 v/v as mobile 
phase and at a flow rate of 1 mL/min. Detection was carried out using a 
UV detector at 247 nm. Liu et al. [36] detected a brand-new impurity by 
RP-HPLC in the prasugrel. The impurity was named as impurity X. 
Impurity X was isolated using semi-preparative HPLC followed by 
characterization using nuclear magnetic resonance spectroscopy and 
LC–MS. The functional mechanism of impurity X was speculated. 
Impurity X could be controlled in the manufacture process of the 
prasugrel active pharmaceutical ingredient effectively. BRC Sekhar 
Reddy and Nallagatla. Vijaya Bhaskar Rao. Reddy and Rao [37] validated 
that RP-HPLC is used for the estimation of dabigatran in bulk and 
pharmaceutical dosage form. It is a simple, precise, accurate RP-LC. The 
HPLC method has been carried out by using Chromasil C18 column. 
This method has been developed using the mobile phase consisting 
methanol: acetonitrile:water 80:15:5 (v/v). pH 4.7 at the flow rate of 
1.0 ml/min by the detection of UV at 280 nm. The retention time of the 
dabigatran is 5.73 min. Ishaq et al [38] developed and validated a 
simple, sensitive, precise, and specific RP-HPLC method for the 
determination of prasugrel in bulk and tablet dosage forms. The HPLC 
separation was carried out by RP chromatography on inertsil ODS-3V 
column (5 μm; 250×4.6 mm) with a mobile phase composed of 0.02 M 
potassium dihydrogen orthophosphate, 0.02 M dipotassium hydrogen 
orthophosphate in water: acetronitrile (30:70 v/v) in isocratic mode at 
a flow rate of 1 ml/min. The detection was monitored at 210 nm. 
Parmar et al. [39] developed RP-LC method for the assay of prasugrel in 
bulk. The chromatography was performed on Kromasil C18 column. 
The eluted compounds were monitored by UV detection at 257 nm 
using mobile phase methanol-potassium dihydrogen orthophosphate 
(pH 2.2; 10 mM) (70:30, v/v). Hadagali [40] developed and validated a 
simple, sensitive, and rugged RP-HPLC method for the determination of 
rivaroxaban in pure, pharmaceutical formulations, and in spiked human 
plasma sample. The separation of rivaroxaban and internal standard 
was achieved on XDB C18 (150×4.6) mm column. Mobile phase 
employed for the study is the mixture of water and acetonitrile in 
gradient program. A flow rate of 1 ml/min was found optimum for the 
study. Srinivas et al. [41] developed a simple, precise, accurate, 
economical, and reproducible RP-HPLC method for estimation of 
dabigatran etexilate mesylate in capsule dosage form. Quantitative 
HPLC was performed with Shimadzu LC 20ATwith Spin chrome 
Software with UV-Visible Detector (SPD-20A), Phenomenex Luna C18, 
5μm, 250×4.6 mm (size) column was used in the study. The mobile 
phase of methanol: eater (70:30) used in this study. The conditions 
optimized were flow rate (1.2 ml/min) and wavelength (230 nm) and 
run time was 10 min, column temperature was maintained at 
500 C. Retention time was found to be 4.60 min. Sonia et al. [42] 
developed and validated of prasugrel hydrochloride 5 mg tablet by RP-
HPLC for precision, accuracy linearity, and robustness. Zorbax, SB-
Phenyl 250×4.6 mm, 5μ in isocratic mode, with mobile phase containing 
buffer (pH 6.5 with TEA and potassium dihydrogen orthophosphate) 
acetonitrile: eater (90:10) [40–60 (v/v)] was used. The flow rate was 
1.2 ml/min and the analyte was monitored at 235 nm. The retention 
time for prasugrel HCL was 11.5 min. Dalmora et al. [43] a stability 
indicating that RP-HPLC method was validated for the analysis of 
rivaroxaban. The method was carried out on a C18 column 
(150 mm×4.6 mm i.d.), maintained at 40ºC. The mobile phase consisted 
of acetonitrile and water (70:30), run isocratically at a flow rate of 
0.7 mL/min, and using a PDA detection at 249 nm. The separation was 
obtained with retention time of 2.9 min. Prajapati and Patel [44] 
described a precise, accurate, and reproducible RP-HPLC method for 
simultaneous estimation of clopidogrel and rivaroxaban. The separation 
was carried by Kromasil C18 column (250×4.6 mm, 5 μ) with UV 
detection at 240 nm. The mobile phase is consisting of acetonitrile and 
water in a ratio of 90:10, v/v and at a flow rate of 1 mL/min. The method 
was linear over the concentration range for clopidogrel 1.0–20.0 μg/mL 
and for rivaroxaban 1.0–20.0 μg/mL. Sriram et al. [45] described the 
development of RP-HPLC method for prasugrel hydrochloride in the 
presence of impurities and degradation products generated from the 
forced degradation studies. Successful separation of the drug from the 
process related impurities and degradation products were achieved on 
Gemini C18 (250×4.6 mm) 5 μm particle size column using RP-HPLC 
method. The isocratic method employed with a mixture of buffer and 
(10%v/v water in acetonitrile) mixture of ratio 30:70, respectively. 
Potassium dihydrogen orthophosphate (0.05 M) is used as buffer. 
Kasad [46] developed and validated a simple, precise, and accurate RP-
HPLC method for assay of rivaroxaban. An isocratic separation was 
achieved using a phenomenex C18 (250×4.6 mm, 5 μm), 100°A particle 
size columns with a flow rate of 1 ml/min and using a PDA detector to 
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monitor the elute at 250 nm. The mobile phase consisted of 
methanol: acetronitrile (50:50 v/v). Raja et al. [47] developed and 
validated a simple, rapid, and reproducible RP-HPLC method for the 
estimation of prasugrel hydrochloride in tablet dosage form. A Zorbax, 
SB-Phenyl 250×4.6 mm, 5μ in isocratic mode, with mobile phase 
containing buffer (pH 6.5 with TEA and potassium dihydrogen 
orthophosphate):acetonitrile: water (90:10) [40:60 (v/v)] was used. 
The flow rate was 1.2 ml/min and the analyte was monitored at 235 nm. 
The retention time for prasugrel HCl was 11.5 min. Rigobello et al. [48] 
a stability indicating that RP-LC method for the determination of 
prasugrel in tablets was developed and validated. Stress testing of 
prasugrel was carried out in accordance with ICH guidelines, where the 
drug was submitted to acidic and basic hydrolysis, oxidative, thermal, 
and photolytic conditions. Prasugrel was unstable under all the 
conditions and the degradations products were analyzed by HPLC-UV. 
Furthermore, two main degradation products found under alkaline and 
thermal conditions were investigated by LC-MS. Based on the 
fragmentation patterns, two products resulted from hydrolysis of the 
acetate ester moiety of prasugrel were observed. Due the chemical 
equilibrium, tautomerism occurs between the ketone and alcohol 
functions justifying the similar molecular weight and fragment pattern 
obtained in degradation products analysis. Successful separation was 
achieved on a RP-18 octadecylsilane column using acetonitrile and TEA 
0.5% mixture (50:50, v/v) as the mobile phase at 25°C. The flow rate 
was 1.0 mL/min and the detector wavelength was 263 nm. Ahirrao 
et al. [49] developed a simple, rapid, and precise method for the 
quantitative estimation of prasugrel hydrochloride in pharmaceutical 
dosage form. A chromatographic separation of prasugrel and its 
degradants was achieved with Zorbax XDB C8, 150×4.6 mm, 3.5 μm 
analytical column using aqueous solution of 0.05 M ammonium acetate 
pH 4.5 with acetic acid-acetonitrile (40:60 v/v). The instrumental 
settings include flow rate of 1.0 ml/min, column temperature at 30°C, 
and detector wavelength of 254 nm using a PDA detector. Modi and 
Pingale [50] developed and validated a new, simple, specific, accurate, 
precise, and rapid RP-HPLC method for the determination of prasugrel 
hydrochloride in pure and tablet dosage forms. The HPLC separation 
was carried out by RP chromatography on Kromasil C18 (100×4.6 mm; 
5 μm) with a mobile phase consist of methanol buffer (680 mg 
potassium dihydrogen phosphate in 500 ml water, pH-2.1 adjusted with 
orthophosphoric acid) in the ratio of 70:30 v/v delivered in isocratic 
mode at a flow rate of 0.8 ml/min. The prasugrel hydrochloride was 
quantified at 220 nm. The retention time of prasugrel hydrochloride 
was 1.9 min. Kumar et al. [51] designed a simple, sensitive, precise, and 
specific RP-HPLC method for the determination of prasugrel in bulk and 
its tablet dosage forms. The HPLC separation was carried out by RP 
chromatography on XTerra column C18 (4.6×150 mm, 5 μm) with a 
mobile phase composed potassium dihydrogen phosphate and the pH 
has been adjusted to 3.0 by Orthophosporic acid and acetonitrile in the 
ration of 40:60 v/v in isocratic mode at a flow rate of 1.0 ml/min. The 
run time has been maintained 5 min. The detection was monitored at 
210 nm. Shivashankar et al. [52] developed and validated a simple 
RP-HPLC method for the estimation of rivaroxaban in formulation. 
A HIBAR-5μ C18 column (250×4.6 mm) was used as a stationary phase. 
The mobile phase consisted of potassium dihydrogen orthophosphate 
buffer (pH adjusted to 3.0 with orthophosphoric acid):acetonitrile in 
the ratio of 60:40 % v/v and the flow rate was 1 ml/min. The detection 
was carried in the room temperature at 248 nm. The retention time of 
rivaroxaban was 7.45 min. Latha et al. [53] developed and validated a 
RP-HPLC method for the determination of dabigatran etexilate mesylate 
(DEM) in bulk form. The chromatography was carried out on Unisol 
C18 (4.6×150 mm, 3 μm) using a mobile phase of methanol and 
ammonium acetate buffer in the ratio of 90:10, at a flow rate of 1 ml/min. 
The analytes were monitored at 226 nm using a PDA detector. The 
retention time of the DEM was 2.52 min. Dare et al. [54] developed the 
stability indicating, highly accurate precise and linear method for 
related substance of the dabigatran through the RP-HPLC. The optimize 
method uses a RP column, Poroshell 120 EC-18 (150 mm×4.6 mm, 
2.7 μ), mobile phase of hexane-1 sulfonic acid sodium salt monohydrate 
(6.5±0.05), and methanol through gradient flow rate of 0.6 ml/min. 
Keeping the column at temperature 30°C and using the sample amount 
10 μL at 5°C and detected all the impurities at 230 nm by the UV 
detector. In the developed method, elution of dabigatran was at 
26.9 min. El Zaher et al. [55] carried a simple, precise, accurate, and 
rapid stability indicating that LC method was developed for the 
determination of dabigatran etexilate mesylate in bulk powder and 
pharmaceutical formulations. Chromatographic separation was carried 
out by isocratic elution on Eclipse XDB C8 (4.6×250 mm, 5 μm) using 
0.01 M orthophosphoric acid (pH 2.6):acetonitrile (60:40 v/v) as the 
mobile phase. The flow rate was 1.5 ml/min and the UV detection was 
done at 225 nm. Linearity was obtained over a concentration range of 
5–100 μg/ml with a regression coefficient of 0.9975. Patel et al. [56] 
developed and validated an accurate, sensitive and rapid RP-HPLC 
method for the estimation of dabigatran etexilate mesylate from capsule 
dosage form. The separation was achieved by a Zorbax C18 column 
(100 mm×4.6 mm, 3.5 μm) in isocratic mode, with mobile phase 
comprises of acetonitrile: water in the proportion of 70:30 v/v. The 
flow rate of mobile phase was 1.0 ml/min, and detection was done at 
225 nm wavelength. The retention time of dabigatran etexilate mesylate 
was 3.0 min. The calibration curve was found to be linear with in the 
concentration range of 20 μg/ml–100 μg/ml. Çelebier et al. [57] 
developed a RP-HPLC method for the determination of rivaroxaban in 
tablets (Xarelto® [10 mg]). Phenomenex Luna 5 μm C18 100 Å LC 
Column (250×4.6 mm) was used at 40°C. Isocratic elution was 
performed with ACN: water (55:45 v/v) mixture. The flow rate was 
1.2 mL/min and UV detection was at 249 nm. Internal standard 
(Caffeine) and rivaroxaban were eluted within 2.21 and 3.37 min, 
respectively. Girase and Soni [58] developed and validated RP-HPLC 
method for the qualitative analysis of rivaroxaban. The chromatographic 
separation was achieved on ZorbaxSB C18 (250 mm×4.6 mm, 3.5 μ) 
HPLC column using buffer (0.02M mono basic potassium dihydrogen 
phosphate) and solvent mixture (acetonitrile: methanol mixture) 
ingradient program. Rajan and Basha [59] developed and evaluated the 
RP-UPLC method for the quantitative determination of potential 
impurities of rivaroxaban active pharmaceutical ingredient. The 
method uses a water acquity BEH C8 column (100 mm×2.1 mm, 1.7 μm) 
with mobile phase A consisted, 0.05M diammonium hydrogen 
phosphate, pH adjusted to 3.0 and acetonitrile (80:20, v/v), and mobile 
phase B consisted mixture of acetonitrile and water (90:10, v/v) with a 
gradient program. The column temperature was maintained at 30ºC 
and the detection was carried out at 254 nm. El-Aziz et al. [60] created 
simultaneous assay method of two anti-platelet drugs, rivaroxaban 
with clopidogrel the developed and validated method is characterized 
by its simplicity, sensitivity, and rapidness. Chromatographic study is 
performed on a 3 mm×4.6 mm i.d., 2 μm pore size highly porous 
monolithic (Chromolith® RP) column to obtain good chromatographic 
separation using a mixture of 0.185 M sodium dodecylsulfate, 8% 
n-propanol, 0.3% TEA as a mobile phase, and adjusted at pH 4.0 using 
0.02 M orthophosphoric acid and pumped at a flow rate of 1 mL/min 
using UV detector at 235 nm. The internal standard (IS) of choice was 
raloxifen and separation was performed at room temperature. Good 
linearity for the proposed method was obtained over the ranges of 0.3–
9.0 μg/mL and 0.5–25.0 μg/mL and retention time was 1.9 and 5min, 
respectively. Meenakshi and Rao [61] developed that simple, rapid, 
accurate, precise, robust, and reproducible RP-HPLC method for the 
determination of rivaroxaban in pure drug and pharmaceutical dosage 
form. The quantification was carried out using enable 
C18 (250×4.6 mm, 5 μm) column in a binary mode with mobile phase 
comprising 0.1% glacial acetic acid: acetonitrile in 30:70% v/v at flow 
rate 1 ml/min, detection was carried out at 250 nm using PDA detector 
with injection volume 20 μl, the retention time was found to be 3.44 min. 
Sahani and Jain [62] developed and validate a simple, rapid, accurate, 
and precise RP-HPLC method for simultaneous estimation of 
drotaverine hydrochloride, ethamsylate, and tranexamic acid in the 
tablet dosage form. Sunny et al. [63] developed RP-HPLC method for the 
quantitative estimation of rivaroxabanin formulation and bulk drug. 
Isocratic elution at a flow rate of 1 ml/min was employed on an Aglient 
Eclipse C8 LC Column (150×4.6 mm) with 5 μm pore size was used at 
400C.The mobile phase consisted of TEA: acetonitrile 85:15 v/v (PH 
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11.6). The UV detection wavelength was at 251 nm and 20 μl, the 
sample was injected at an interval of 5 min. Retention time for 
rivaroxaban was 1.56 min. Prajapati et al. [64] carried stability-
indicating HPTLC method for the estimation of dabigatran etexilate 
mesylate using TLC plates pre-coated with silica gel 60 F254 as 
stationary phase and toluene: ethyl acetate: methanol:formic acid 
(3:4:3:0.2, v/v/v/v) as the mobile phase. The wavelength selected for 
quantitation was 314 nm. The method was linear in the concentration 
range 50–250 ng/spot with a correlation coefficient of 0.9955. Vaghela 
and Patel [65] developed and validated HPTLC, simple, precise, 
accurate, and specific chromatographic method for the determination 
of rivaroxaban from its tablet dosage form. The mention drug was 
spotted on silica gel F254 TLC plates under pure nitrogen stream by 
Linomat TLC spotter. Separation was carried out using methanol, 
toluene, and triethanolamine as mobile phase in ratio of 7:2.5:0.5 v/v/v. 
Developed TLC plates were scanned by CAMAG TLC scanner and 
detection was carried out at 249 nm. Rf value of separated drug was 
found to be 0.60 for rivaroxaban. The linearity of rivaroxaban is 500–
3000 ng/spot. Srikanth et al. [66] proposed that simple, sensitive and 
precise RP-HPLC method has been developed for the estimation of 
prasugrel hydrochloride in pharmaceutical dosage forms. The mobile 
phase consist of buffer (0.02 M sodium dihydrogen phosphate, pH-3 
adjusted with orthophosphoric acid):methanol: acetonitrile in the ratio 
of 45:20:35v/v delivered at a flow rate of 1.0 ml/min and wavelength of 
detection at 220 nm. The retention time of prasugrel hydrochloride was 
8.2 min. Abu Ruzilawati and Miran [67] discussed and developed that 
methamphetamine is one of the illicit drugs, which are common among 
students and teenagers. Methamphetamine was found to be the most 
commonly abused amphetamine-type stimulants compared with other 
types of amphetamines. Therefore, fast and reliable detection of these 
drugs is important in toxicology and doping control. Many extraction 
methods such as solid phase (SPE) and SPE microextraction have been 
used for extraction of methamphetamine in the biological fluid. The 
objective of this study was to develop an effective liquid-liquid 
extraction method form ethamphetamine in human urine. Optimization 
of the extraction method was done by varying the types of solvents used 
to extract the drug from the urine. The percentage recovery of 
methamphetamine extraction was investigated using a variety of 
extracting solvents (ethyl acetate, dichloromethane, diethyl ether, and 
chloroform) and solvents system (chloroform: isopropanol [9:1] and 
chloroform: ethyl acetate: ethanol [3:1:1]). The analysis of the extracted 
drug was done by HPLC equipped with fluorescence detector. 
Optimization of chromatographic conditions was also done by varying 
the pH’s of mobile phase and the composition of the mobile phase. The 
extracting solvent system that consists of chloroform: ethyl 
acetate: ethanol (3:1:1) gave the highest recovery, which is 87%. The 
optimized HPLC condition used for the analysis was a mixture of 
acetonitrile and deionized water at pH 2.4 in the ratio of 15:85 v/v with 
a flow rate of 0.6 mL/min.
LC-MS
Antovic et al. [68] carried that dabigatran concentration in plasma 
was determined using LC-MS/MS. Chromatographic separation of the 
analytes was achieved on an Acquity UPLC BEH column (Shield RP18, 
2.1×50 mm, 1.7 μm) using a gradient run with mobile phase A (10 mM 
ammonium formate pH 4.5) and mobile phase B (0.1% formic acid 
in acetonitrile). The analytes were detected using a Waters Quattro 
Premier XE mass spectrometer operating in positive electrospray 
ionization (ESI) mode, utilizing selected reaction monitoring (SRM) 
with ion transitions 472→289 m/z for dabigatran and 475→292 m/z 
for the internal standard. The total analysis time was 3 min. Srikanth 
and Rani [69] developed and validate a LC–MS/MS for the quantification 
of lenvatinib (LT) in human plasma. A simple, sensitive, and specific 
LC–MS/MS method was developed for quantification of LT in human 
plasma using LTD4 as internal standard (IS). The analytical method 
consists of liquid–liquid extraction of plasma sample followed by the 
determination of LT by an LC–MS/MS. The analyte was separated on a 
Zorbax Eclipse XDB-C18 (150×4.6 mm, 5 μ) column with an isocratic 
mobile phase of acetontrile:0.1% formic acid (80:20 v/v) at a flow rate 
of 0.6 mL/min. The product ions were formed by a turbo lon spray in a 
positive mode were used to detect analyte and IS. The MS/MS detection 
was made by monitoring the fragmentation of m/z 427.10→370.10 for 
LT and m/z 430.30→370.10 for IS on a MS. Schmitz et al. [70] carried 
out determination of dabigatran, rivaroxaban, and apixaban by UPLC-
MS/MS and coagulation assays for therapy monitoring of novel direct 
oral anticoagulants. Zhang et al. [71] established a rapid and sensitive 
UPLC–MS/MS method for the determination of rivaroxaban, apixaban, 
and edoxaban in rat plasma. The analytes and the internal standard 
(diazepam) were separated on an Acquity UPLC BEH C18 chromatography 
column (2.1 mm, 9.50 mm, 1.7 µm) using gradient elution with a mobile 
phase of acetonitrile and 0.1% formic acid in water at a flow rate of 
0.4 mL/min. The detection was performed on a triple quadrupole MS/
MS by multiple reaction monitoring mode to monitor the precursor-to-
product ion transitions of m/z 436.1 → 145.1for rivaroxaban, m/z 460.0 
→ 443.1 for apixaban, m/z 548.2 →366.1 for edoxaban, and m/z 285.2 → 
193.1 for diazepam (IS) using a positive ESI interface. The method was 
validated over a concentration range of 1.0–200 ng/mL for rivaroxaban, 
1.0–100 ng/mL for apixaban, and 1.0–500 ng/mL for edoxaban. Total 
time for each chromatograph was 3.5 min. Reddy et al. [72] developed 
and validated a HPLC-MS/MS technique for the determination of 
rivaroxaban in human plasma. The samples were extracted using 
solid-phase extraction (SPE) technique wherein rivaroxaban D4 has 
been used as the internal standard. The use of isocratic LC method 
has enabled to achieve 2.0 min along with their respective internal 
standard using a Phenomenex Gemini C18, 50×4.6 mm, 5 μm column. 
ESI source in positive mode was used for the detections of rivaroxaban 
and IS. Precursor to product ion transition of m/z 436.20 → 144.80 
for rivaroxaban and m/z 440.20 →144.70 for IS was used in multiple 
reaction monitoring mode. Derogis et al. [73] proposed that a HPLC-
MS/MS method was validated to measure rivaroxaban plasmatic 
concentration. In this method used a simple sample preparation, 
protein precipitation, and a fast chromatographic run. It was developed 
a precise and accurate method, with a linear range from 2 to 500 ng/mL, 
and a lower limit of quantification of 4pg on column. The new method 
was compared to a reference method (anti-factor Xa activity) and 
both presented a good correlation (r=0.98, p<0.001). In addition 
authors are validated hemolytic, icteric or lipemic plasma samples for 
rivaroxaban measurement by HPLC-MS/MS without interferences. The 
chromogenic and HPLC-MS/MS methods were highly correlated and 
should be used as clinical tools for drug monitoring. Puram et al [74] 
evaluated the levels in plasma of pyridostigmine impurity B (metabolite 
of pyridostigmine) in humans after administration of pyridostigmine 
formulations. Plasma concentrations of pyridostigmine impurity 
B were estimated using by LC coupled with ESI triple quad mass 
spectrometer technique, lamivudine is used as an internal standard. 
Multiple reactions at 109.9/95.2 (pyridostigmine impurity B) and 
230.2/112.2 (lamivudine) were monitored. Chromatography was 
optimized using acetonitrile: buffer (10 millimolar ammonium acetate) 
(85:15) on an Inertsil C18, 150 mm×4.6 mm, 5 μ analytical column. 
The Linear Calibration curve was ranges between 1.434 ng/ml and 
39.637 ng/ml. Sample extraction was conducted using SPE extraction 
method using mixed mode cation exchange cartridges. The method was 
developed on API 4000. The method was developed, tested for system 
suitability, carryover, selectivity, matrix effect, intra-inter precision 
and accuracy, recovery, linearity, and various stabilities in aqueous as 
well as plasma as a matrix. The method was validated for all the above 
validation parameters mentioned as per European medical agency 
guideline on method validation. Yadav and Dubey [75] successfully 
developed a sensitive and accurate LC method for the quantification 
of rivaroxaban in human plasma. Protein precipitation was used 
for sample preparation. Quantification of analyte was achieved 
on phenomenex luna C8 (5 μm×25 cm×4.6 mm i.d.) column using 
methanol: water:dimethyl sulfoxide (50:45:5, v/v/v) as mobile phase 
at a flow rate of 1 ml/min. Detection was achieved at 252 nm over the 
linearity concentration range of 5–40 μg/ml. Retention time was found 
6.2 min. The Limit of detection and limit of quantification were found 
to be 1.5 μg/ml and 4.5 μg/ml, respectively. The developed method was 
validated as per the US FDA guidelines.
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CONCLUSION
Most of the techniques such as spectrophotometric and chromatography 
RP-HPLC and LC coupled with MS/MS methods have been applied 
when dabigatran, rivaroxaban, and prasugrel are in pure form and its 
formulations. As far as, we know there is not a single research paper 
which refers to the quantification of dabigatran, rivaroxaban, and 
prasugrel by applicability quality by design. Hence, there is still scope 
for the development of new selective and specific analytical techniques 
for quantization of these molecules.
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